Education
About Us
Working with TipRanks
Follow Us
Vicarious Surgical (RBOT)
NYSE:RBOT
RBOT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.27 - $19.00
Previous CloseN/A
Volume30.88K
Average Volume (3M)27.80K
Market Cap
$55.29M
Enterprise Value$15.01M
Total Cash (Recent Filing)$37.36M
Total Debt (Recent Filing)$13.50M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Aug 12, 2025EPS Estimate
-2.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding5,278,175
10 Day Avg. Volume27,615
30 Day Avg. Volume27,805
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$13.00Price Target Upside39.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Investor SentimentRBOT is planning to submit a technical dossier that will enable treatment of first clinical patients, significantly boosting investor sentiment.
Supply Chain ManagementRBOT has effectively managed supply constraints with no new adjustments to its development or clinical timelines.
Bears Say
Development DelaysDevelopment milestones and timelines were shifted back 3 to 6 months due to supplier dynamics which have limited key parts within the Vicarious System.
Financial ConcernsThe company will need to either reduce cash burn or find some sources of non-dilutive financing.
Vicarious Surgical News
RBOT FAQ
What was Vicarious Surgical’s price range in the past 12 months?
Vicarious Surgical lowest stock price was $4.27 and its highest was $19.00 in the past 12 months.
What is Vicarious Surgical’s market cap?
Vicarious Surgical’s market cap is $55.29M.
When is Vicarious Surgical’s upcoming earnings report date?
Vicarious Surgical’s upcoming earnings report date is Aug 12, 2025 which is tomorrow.
How were Vicarious Surgical’s earnings last quarter?
Vicarious Surgical released its earnings results on May 12, 2025. The company reported -$2.58 earnings per share for the quarter, missing the consensus estimate of -$2.48 by -$0.1.
Is Vicarious Surgical overvalued?
According to Wall Street analysts Vicarious Surgical’s price is currently Undervalued.
Does Vicarious Surgical pay dividends?
Vicarious Surgical does not currently pay dividends.
What is Vicarious Surgical’s EPS estimate?
Vicarious Surgical’s EPS estimate is -2.5.
How many shares outstanding does Vicarious Surgical have?
Vicarious Surgical has 5,278,175 shares outstanding.
What happened to Vicarious Surgical’s price movement after its last earnings report?
Vicarious Surgical reported an EPS of -$2.58 in its last earnings report, missing expectations of -$2.48. Following the earnings report the stock price went down -10.936%.
Which hedge fund is a major shareholder of Vicarious Surgical?
Currently, no hedge funds are holding shares in RBOT
Vicarious Surgical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (39.48% Upside)
$13.00 (39.48% Upside)
Insider Transactions
Sold Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.04%
12-Months-Change
Fundamentals
Return on Equity
-104.36%
Trailing 12-Months
Asset Growth
-47.71%
Trailing 12-Months
Company Description
Vicarious Surgical
Vicarious Surgical (RBOT) is a medical technology company that specializes in developing innovative robotic systems designed to enhance minimally invasive surgery. The company's core product is its advanced robotic platform, which integrates proprietary human-like surgical robots with 3D visualization and AI-driven insights to improve surgical precision and outcomes. Vicarious Surgical aims to revolutionize the field of surgery by providing surgeons with enhanced capabilities, improved ergonomics, and reduced procedure times.
RBOT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic partnerships and progress toward clinical milestones while acknowledging ongoing challenges with cash burn and regulatory processes. Despite some concerns, there is optimism about achieving major milestones in 2025.View all RBOT earnings summariesRBOT Stock 12 Month Forecast
Average Price Target
$13.00
▲(39.48% Upside)
Technical Analysis
Ownership Overview
2.04% Insiders
3.83% Mutual Funds
29.01% Other Institutional Investors
62.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---